| Identification | Back Directory | [Name]
C6 NBD-Sphingosine, beta-D-lactosyl | [CAS]
474943-04-9 | [Synonyms]
C6 NBD Lactosylceramide (d18:1/6:0)
C6 NBD-Sphingosine, beta-D-lactosylsphingosine
N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)aMino]hexanoyl]-D-lactosyl-1-1'-sphingosine
N-[6-[(7-NITRO-2-1,3-BENZOXADIAZOL-4-YL)AMINO]HEXANOYL]-D-LACTOSYL-1-1'-SPHINGOSINE;C6-NBD LACTOSYL CERAMIDE
Hexanamide, N-[(1S,2R,3E)-1-[[(4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]- | [Molecular Formula]
C42H69N5O16 | [MDL Number]
MFCD03428077 | [MOL File]
474943-04-9.mol | [Molecular Weight]
900.02 |
| Hazard Information | Back Directory | [Description]
C6 NBD Lactosylceramide (d18:1/6:0) is a biologically active derivative of lactosylceramides (d18:1/acyl mixture) that is tagged with a fluorescent C-6 nitrobenzoxadiazole (C-6 NBD; ) group.1 C6 NBD Lactosylceramide (d18:1/6:0) has been used to study the effects of P-glycoprotein inhibition in lactosylceramide metabolism-based therapeutics for the treatment of cancer. As this product is derived from a natural source, there may be variations in the sphingoid backbone. | [References]
1. Morad, S.A., Davis, T.S., MacDougall, M.R., et al. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer Biochem. Pharmacol. 130,21-33(2017). |
|
| Company Name: |
Alfa Chemistry
|
| Tel: |
1-516-6625404 |
| Website: |
https://www.alfa-chemistry.com |
| Company Name: |
Creative Enzymes
|
| Tel: |
1-516-855-7709 |
| Website: |
www.creative-enzymes.com |
|